Article

HSO suspends clear-optic IOL sales

HOYA Surgical Optics, Inc. (HSO) announces that it has voluntarily suspended sales of two models of its clear-optic IOLs: the iSymm IOL (Model FC-60AD) and the iSert IOL (Model PC-60AD). This action affects only U.S. customers, and HSO has requested the return of these lenses.

Chino Hills, CA-HOYA Surgical Optics, Inc. (HSO) announces that it has voluntarily suspended sales of two models of its clear-optic IOLs: the iSymm IOL (Model FC-60AD) and the iSert IOL (Model PC-60AD). This action affects only U.S. customers, and HSO has requested the return of these lenses.

HSO has been working with the FDA to resolve an issue regarding the approval status of the clear-optic lenses, and believes that the regulatory process will be more efficient if the lenses are returned while it continues to work with the FDA.

“[The] FDA has informed us [that] they have not yet approved these lens models, and we have filed additional data as requested by them to obtain FDA approval. While we are disappointed [that] this recall is required, we remain strongly committed to our U.S. customers and believe that our actions demonstrate our intent to work closely with them and the FDA to provide the same outstanding products and services that have allowed us to become the fastest-growing IOL company in the U.S.,” said Steven L. Ziemba, HSO’s vice president of global regulatory affairs.

For assistance, customers can call HSO toll-free, at 866/750-5870.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.